HIGHLIGHTS
- who: Austin T. Mefford from the School of Medicine, University of Texas Medical Branch, Galveston, TX, USA have published the Article: Peyronieu2019s disease - outcomes of collagenase clostridium histolyticum injection: A systematic review, in the Journal: (JOURNAL) of 29/05/2021
- what: Since the approval of CCh by the United States Food and Drug Administration in2013 it has been a staple in the treatment of PD and here the authors report the continuedsuperiority of this therapy. In 1995, INF alpha-2b was first studied in patients with PD and the conclusion of the study showed disappointing . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.